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Summary 
Reperfusion ofischemic tissue induces an acute inflammatory response that can result in necro- 
sis and irreversible cell injury to both local vascular endothelium and parenchyma. To examine 
the pathogenesis of ischemia/reperfusion injury, we have used mice deficient in complement 
components C3,  C4, or serum immunoglobulin in a hindlimb model of ischemia. We found 
that mice homozygous deficient in C3 or C4 were equally protected against reperfusion injury 
based on a significant reduction in leakage of radiolabeled albumin out of the vasculature. This 
demonstrates that classical pathway complement is an important factor in the initiation ofinflam- 
marion following reperfusion.  Furthermore,  mice  deficient in  serum  immunoglobulin  were 
equally protected and this protection could be reversed by reconstitution with serum from nor- 
real mice. Thus, this report describes a novel mechanism for reperfusion injury that involves 
antibody deposition and activation of complement leading to inflammation permeability. 
W 
hile  the  pathogenesis  of reperfnsion  injury  is  not 
completely understood,  the  complement system is 
thought to be involved since there is clear evidence of dep- 
osition of complement components C5-9 after repeffusion 
of hypoxic tissue (1, 2)  and injury can be inhibited in part 
by pretreatment with soluble complement receptor type 1 
(sCR1) (3-6). Weisman et al. found that pretreatment with 
sCR1  substantially reduced  influx  of neutrophils,  deposi- 
tion of C5-9 and myocardial infarct size in a rat model of 
myocardial ischemia (3). Similar studies have used sCR1  to 
block or reduce inflammation after reperfusion ofischemic 
rat hindlimb or intestine and of mouse skeletal muscle (cre- 
master) (4-6). Complement receptor type 1 (CR1; CD35), 
which  is  normally  expressed  by  human  erythrocytes,  B 
lymphocytes,  granulocytes,  and  macrophages,  binds  acti- 
vated C3  (C3b) and C4 (C4b) leading both to dissociation 
of the complement system's C3 and C5 activating enzymes 
and to proteolytic degradation of C3b and C4b by serum 
factor I.  When  administered in  a  soluble  form,  recombi- 
nant sCR,1  functions  as a highly effective inhibitor  of se- 
rum complement activation (7). 
To clarify the role of complement and gain insight into 
the  pathogenesis  of ischemia/reperfusion injury,  we  have 
examined novel strains of mice deficient in either comple- 
ment components C3 or C4 in a mouse model ofhindlimb 
ischemia  reperfusion.  Both  strains  of mice  were  equally 
protected from vascular injury demonstrating that injury is 
mediated by the classical  pathway. Moreover, mice totally 
deficient in antibody, i.e., recombination-activation gene 2 
deficient  (RAG-2-/-)  (8),  were  equally  protected  and 
protection could be abrogated by reconstitution with fresh 
mouse serum. These results support the hypothesis that is- 
chemia/reperfusion injury is  initiated  by natural  antibody 
binding  to  hypoxic  endothelium  and  activation  of  the 
complement system. 
Materials and Methods 
Reconstitution of  Antibody-d!ficient Mice.  RAG2-/-  mice  were 
reconstituted  by i.v.  administration  of 0.5  ml of pooled serum 
from control mice 15 h before ischemia. Strain FVB mice were 
used as controls since the RA G2-/-  allele had been backcrossed 
onto  that background.  Circulating  Ig levels were  confirmed as 
"50% normal by ELISA. Briefly, 96-well plates were coated with 
rabbit  anti-mouse Fc  (diluted in carbonate  buffer, pH 9.5) and 
following blocking with 5% milk protein, dilutions of serum from 
control mice or reconstituted  RAG2-/-  mice were added for 
2 h at room temperature.  After wash, a detection antibody (alka- 
line-phosphatase  conjugated  goat anti-mouse IgG or IgM) was 
added  for  1 h  followed  by color  substrate  (Sigma 105; Sigma 
Chem. Co., St. Louis, MO). Serum samples and detection  anti- 
bodies were diluted with 5% milk protein in phosphate-buffered 
saline, pH 7.5.  Following  addition  of substrate,  O.D.  540  was 
measured in a Micro-titer plate reader. 
Hindlimb Model of lschemia/repegCusion Injury.  Mice underwent 
2 h of hindlimb  ischemia and 3 h of reperfusion  as described (4). 
Bilateral tourniquets  were placed above the greater trochanter of 
pentobarbital  anesthetized mice (20-35  g). Sham controls did not 
undergo  ischemia.  5  rain before tourniquet  release animals re- 
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Wildtype  C3-/-  C4-/-  sCR1  Sham 
Figure 1.  Ischemia/reperfusion injury is mediated by classical  pathway 
of complement. Mice underwent 2 h of hindlimb ischemia and 3 h of 
repeffusion. Hindlimb PT was reduced significantly  (P <0.05) in C3-/-, 
C4-/-  and sCR.1 treated compared to  complement  sufficient litter- 
mates. The group treated with sCR1 received 20 mg/kg before tourni- 
quet release. The hindlimb permeability index (P.I.) was determined by 
the ratio (CPM/g dry muscle)/(CPM/g  blood). Error bars represent the 
standard error of the mean and significance  at P <0.05 is indicated by an 
asterisk. 
FVB  RAG2-/-  RAG2-/-  Sham 
+ Serum 
Figure 2.  Antibody is important in ischemia/reperfusion injury. Ische- 
mia/reperfusion injury was induced in RAG2-/- or control mice as de- 
scribed in Fig. 1. RAG2-/- mice (strain FVB background) were recon- 
stituted by i.v. administration of 0.5 ml of pooled serum from control 
mice (strain FVB) 15 h before ischemia. RAG2-/-  mice had a signifi- 
cant reduction  in P.I.  (P <0.05)  (indicated by asterisk) which was re- 
versed by addition of normal serum (P <0.05). 
ceived  1  p~Ci 12SI-labeled  albumin  intravenously.  The  group 
treated with sCR.1 received 20 mg/kg at the same time as radio- 
labeled albumin. Tourniquets were removed and limb reperfusion 
was confirmed by return of pink color. Animals received 0.1 ml of 
0.9% saline intraperitoneal during each hour or repeffusion. Fol- 
lowing euthanasia hindlimb muscle was harvested bilaterally, its 
radioactivity measured, and dried to a constant weight at 90~  for 
3 d.  The hindlimb permeability index (P.I.) was  determined by 
the ratio (CPM/g dry muscle)/(CPM/g blood). 
Statistics.  Groups were subjected to analysis  of variance fol- 
lowed by Student's t-test with the Bonferroni correction for mul- 
tiple comparisons. 
Immunohistological  Analysis.  Immunoperoxidase labeling of IgM, 
IgG and C3 was performed on paraformaldehyde-fixed cryostat 
serial sections  of hindlimb muscle  using goat  anti-mouse  IgM 
(Sigma),  goat  anti-mouse  IgG  (Sigma)  or goat anti-mouse C3 
(5 ~g/rnl)  (Organon Teknia, Durham,  NC)  and a standard avi- 
din-biotin protocol (9). 
Results and Discussion 
Mice deficient in either C3  (C3-/-)  or C4  (C4-/-) 
were  constructed  using the  techmque  of homologous  re- 
combination in embryonic stem cells (ES)  and both strains 
had  undetectable levels of serum  C3  (10)  or C4  (Fischer, 
M.B.,  M.  Ma,  S.  Goerg,  X.  Zhou, J.  Xia,  O.  Finco,  S. 
Hans,  G.  Kelsoe,  P,.G.  Howard,  T.L.R.othstein  et  al., 
manuscript submitted for publication), respectively. 
The  extent  of  complement-mediated  damage  in  the 
hindlimb model of ischemia/reperfusion injury was exam- 
ined  by  comparing  the  complement-deficient  mice,  i.e., 
C3-/-  and C4-/-,  with normal littermates. Hindlimbs 
of treated animals were made ischemic for 2 h  followed by 
3  h  of repeffusion. Subsequently, both right and left hind- 
limbs were harvested for analysis. Injury, i.e., vascular leak- 
age,  was  evaluated by administering radiolabeled albumin 
immediately before repeffusion and comparing the level of 
radioactivity in dry muscle to that of blood. 
Reperfusion of ischemic skeletal muscle resulted in en- 
dothelial cell injury characterized by vascular leakage with 
permeability edema.  The  muscle permeability index  (P.I.) 
of normal complement-sufficient mice (n =  19) was 2.47  + 
0.19  (mean  +  standard error)  compared to sham  animals, 
0.15  +  0.01.  In contrast,  C3-/-  (n  =  13)  animals had a 
significant (P <0.05) reduction in vascular leakage, i.e., P.I. 
2344  Reperfusion Injury Is Mediated by Natural Antibody and Complement Figure 3.  Ischemia/reperfusion  injury results in deposition of IgM (A) and C3 (B) on vascular endothetium. Immunoperoxidase  labeling of IgM and 
C3 was performed on paraformaldehyde-fixed  cryostat serial sections of hindlimb muscle using goat anti-mouse IgM and C3 (5 jzg/ml) and a standard 
avidin-biotin protocol (9). No staining was seen with irrelevant goat IgG (5/~g/ml) (C) or with muscle samples from sham mice (D-F, anti-IgM, anti-C3 
and irrelevant goat IgG, respectively). Results were similar in three mice analyzed  per group. Original magnification, 200X. 
of 1.25  +  0.11  (Fig.  1). Thus, deficiency in C3, which im- 
pairs both pathways of complement,  resulted in a  50% re- 
duction in injury. To correlate this result with earlier reports 
that used sCR1  to block C3 activation, complement-suffi- 
cient mice  (n  =  12)  were treated with sCR1  immediately 
before reperfusion.  Treatment with sCR1  reduced vascular 
injury, i.e.,  1.25  +  0.06, to a level similar to that observed 
in the C3-/-  mice (Fig.  1). 
The  complement system can be  activated by either the 
classical or the alternative pathways (11). While the classical 
pathway is  generally activated by antibody,  the  alternative 
pathway can activate spontaneously and is tightly regulated 
by "regulators of complement activation"  (12,  13).  There- 
fore, as a first step towards defining the mechanism of com- 
plement-mediated  ischemia/reperfusion  injury,  it was im- 
portant  to  determine  which  pathway  was  being  activated 
by hypoxic endothelium.  To test the hypothesis that classi- 
cal pathway  was involved,  C4-/-  mice,  which  have  an 
intact  alternative  pathway but can not form classical path- 
way C3 convertase (C2aC4b), were compared in the hind- 
limb model. Interestingly, the C4-/-  mice (n =  12) were 
protected  to  a  similar  degree  as  the  C3-/--  and  sCR1- 
treated  mice,  i.e.,  P.I.  of 1.56  +  0.21  (Fig.  1).  Thus,  the 
extent of  vascular leakage due to complement injury is me- 
diated by activation of the  classical  and not the alternative 
pathway. 
A principal mechanism for activation of classical pathway 
of complement  is  serum  antibody.  To  determine  if the 
complement-mediated  injury  observed  in  the  hindlimb 
model was initiated by antibody, mice deficient in recom- 
bination-activation  gene  2  (RAG2-/-)  (8)  were  ana- 
lyzed.  The  antibody-deficient  mice  were  protected  to  a 
similar level as the C3-/-  and C4-/-  mice, i.e.,  1.82  + 
0.25 (n =  8) vs. 3.45  +  0.17  (n =  11) for RAG2-/-  and 
FVB controls, respectively (Fig. 2). 
Since RAG2-/-  mice also lack mature B  and T  lym- 
phocytes, it was important  to demonstrate  that the reduc- 
tion  in vascular permeability  was not a  cellular  effect.  To 
distinguish  serum  from  cellular  effects,  RAG2-/-  mice 
were  reconstituted  (intravenously)  with  0.5  ml  of pooled 
normal mouse serum and treated as described above in the 
hindlimb  model.  Analysis  of the  mice,  demonstrated  that 
pooled serum restored the level of injury to that of normal 
FVB controls, i.e., 3.45 -4- 0.50 (n =  5) vs. 3.45  +  0.17 (n = 
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immunoglobulin  is  required for ischemia/reperfusion in- 
jury in the hindlimb model. 
To further evaluate the nature of the antibody involved 
in injury to hypoxic endothelium, sections ofreperfused or 
sham  control hindlimb  tissues  were  stained  with  antisera 
specific for mouse IgG or IgM. As shown in Fig.  3 A, IgM 
was  deposited on vascular endothelium  of hindlimb  har- 
vested from repeffused mice but  absent  in  sham controls 
(Fig.  3 D). Although staining for IgG did not appear spe- 
cific in the reperfused hindlimb, a role for IgG can not be 
excluded (data  not  shown).  This result demonstrates  that 
IgM binds to local vascular endothelium following reperfu- 
sion of ischemic hindlimb and supports the finding above 
that reconstitution of RAG2-/-  mice with normal serum 
restores their inflammatory response. 
Further support for a role of antibody and complement 
in  mediating injury,  comes from the  results  of immuno- 
staining sections of injured hindlimb with antibody to C3. 
C3  deposition colocalized with IgM on the local vascular 
endothelium  of  reperfused  complement-su~cient  mice 
(Fig.  3  B) but was absent in sham controls (Fig.  3 E) and 
treated C3-/-  mice as expected (data not shown). In ad- 
dition,  C3  deposition was  seen on the  skeletal muscle of 
reperfused hindlimbs of control mice but it is not clear if 
this represents C3 activated by classical or alternative path- 
way since deposition of IgM was not observed in this re- 
gion. 
The most probable explanation for the observations that 
deficiency  in  either  classical  pathway  complement,  i.e., 
C3-/-  or C4-/-,  or serum antibody impairs ischemia/ 
reperfusion injury by a similar level (50%),  is that inflam- 
mation is  initiated by deposition of antibody on hypoxic 
endothelium. While the remaining 50% of vascular perme- 
ability is not explained by these results,  it seems highly un- 
likely that the observed complement- and antibody-medi- 
ated  injuries  are  independent  of each  other.  Two  major 
mechanisms by which antibody initiates inflammation are 
activation of classical pathway complement, i.e., binding of 
Clq, or binding to Fc receptors (FcR) on leukocytes. The 
later  effector mechanism  has  been  described for the  IgG 
and  IgE  isotypes but  not for IgM  (14).  Thus,  binding of 
IgM in the absence of complement would not be expected 
to induce inflammation and vascular leakage. 
A possible explanation for the binding of IgM antibody 
in  reperfused vessels  is  that  novel antigenic  determinants 
may  be  exposed  as  a  result  of subtle  alterations  in  the 
plasma membrane following ischemia. Two possible mech- 
anisms for hypoxia-mediated membrane disruption that are 
not mutually exclusive are:  (a) a reduction in phospholipid 
biosynthesis,  or  (b)  activation  of Ca+ +-dependent  phos- 
pholipase and proteases. Alternatively, hypoxia induces en- 
dothelial cell release of preformed products or synthesis  of 
novel membrane-associated proteins (15).  These novel de- 
terminants could serve as targets for binding of circulating 
natural  (preexisting)  antibody.  Although  the  function  of 
natural antibodies is not clear, it is generally held that they 
represent the prod(act of germ-line genes (16) and they are 
often implicated in autoimmune vasculitis  (17). Anti-endo- 
thelial cell  (anti-phospholipid) antibodies have been found 
in sera of normal individuals and it has been postulated that 
alteration in the membrane of endothelial cells whether by 
exposure of existing negatively charged phospholipids  or 
by induction of new determinants results in specific bind- 
ing (17-21).  Thus, in the proposed model, reperfusion of 
hypoxic vessels  results  in binding of natural antibody and 
activation of the classical pathway of complement. 
Previous studies examining activation of complement in 
various  models  of ischemia/reperfusion  have  found  evi- 
dence in support of both pathways.  For example, Lindsay 
et  al.  found  that  classical  but  not  alternative  pathway  of 
complement was consumed in their model ofhindlimb ische- 
mia in the rat (4). In contrast, studies using a mouse skeletal 
model  (cremaster)  of ischemia/reperfusion concluded that 
alternative pathway was responsible for injury since serum 
from mice treated with sCR1  retained classical but not al- 
teruative pathway activity in an in vitro hemolytic assay (6). 
Similarly, in a pig myocardial infarct model of reperfusion 
injury, activated factor B  (alternative pathway) was found 
in serum of ischemic but not sham controls within 15 rain 
after reperfusion (22).  While it is possible that the patho- 
genesis of injury varies in each model, a unifying explana- 
tion is  that  classical  pathway complement is  required for 
initial activation, i.e., by formation of C3  convertase, and 
the alternative pathway is subsequently activated and com- 
ponents such as factor B  are consumed.  Other differences 
such  as  blocking of classical  pathway  in  vivo but  not  in 
vitro could be explained by the sensitivity of the different 
assays. 
Activation of complement has varied effects on initiation 
of local injury. Integration of the terminal components of 
complement C5-C9 in the membrane of vascular endothe- 
lium disrupts cell function and leads  to injury as discussed 
above (1, 2). In addition, release of anaphylatoxins C3a and 
C5a  induce vascular leakage and  enhance infiltration and 
activation of neutrophils (11). Moreover, adhesion and ex- 
travasation of neutrophils is enhanced by covalent deposi- 
tion ofiC3b at the site of activation (23). A role for neutro- 
phils in ischemia/reperfusion injury has been demonstrated 
as depletion or blocking of neutrophil adhesion with anti- 
body  to  B2  integrins  or L-selectin reduces  inflammation 
(24-27).  It is likely that  neutrophil-mediated injury is  in 
part independent of complement activation and this would 
explain  the  residual vascular leakage  in  the  complement- 
and antibody-deficient mice. 
To our knowledge this is the first demonstration that se- 
rum antibody is directly involved in ischemia/reperfusion 
injury. Thus, the novel concept that is emerging is that se- 
rum  antibody  recognizes  neo-determinants  on  damaged 
endothelium  (owing  to  hypoxia  in  our  model)  and  on 
binding to the cell surface initiates inflammation by activat- 
ing the classical pathway of complement. 
2346  Reperfusion Injury Is Mediated by Natural Antibody and Complement The authors wish to thank Drs. Fred Alt and Ben Rich for the RAG2-/-  mice; Dr. Morris Kamovsky for 
helpful review of the manuscript; D. Smith for valuable help with the surgical preparations, A.C. Imrich for 
performing the immunohistochemistry, E. Kremmer (Mmfich,  Germany) for the rat monoclonal antibodies 
and R. Ogata (La Jolla, CA) for the rabbit anti-mouse C4 antisera. 
Supported in part by National Institutes of Health  grants  GM  52585-01,  GM07560-18,  GM35141-09; 
AI32544-03  (M.C.  Carroll); HD17461  (M.C.  Carroll); Arthritis Foundation Biomedical Science  Grant 
(M.C. Carroll); The Brigham Surgical Group, Inc.; and The Trauma Research Foundation. 
Address correspondence to Michael C.  Carroll, Department of Pathology, Harvard Medical School, 200 
Longwood Ave., Boston, MA 02115 or Herbert Hechtman, Department of Surgery, Brigham and Women's 
Hospital, 75 Francis St., Boston, MA 02115. 
Received  for publication  26January  1996 and in revised form  13 March  1996. 
References 
1.  Hugo,  F.,  T.  Hamdoch,  D.  Mathey,  H.  Schafer,  and  S. 
Bhakdi. 1990.  Quantitative measurement ofSC5-9 and C5-9 
(m) in infarcted areas of human myocardium. Clin.  Exp. Im- 
munol. 81:132-136. 
2.  Schafer,  P.J.,  D.  Mathey,  F.  Hugo,  and  S.  Bhakdi.  1986. 
Deposition of the terminal C5b-9 complex in infarcted areas 
of human myocardium.J. Immunol.  137:1945-1949. 
3.  Weisman, H.F., T. Bartow, M.K. Leppo, H.C. Marsh, G.R. 
Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L. Weis- 
feldt, and D.T.  Fearon.  1990.  Soluble human  complement 
receptor type 1: in vivo inhibitor of complement suppressing 
post-ischemic myocardial inflammation and necrosis. Science 
(Wash.  DC). 249:146-151. 
4.  Lindsay,  T.F., J.  Hill,  F.  Ortiz,  A.  Rudolph,  C.R.  Valeri, 
H.B.  Hechtman,  and  F.D.  Moore, Jr.  1992.  Blockade  of 
complement activation prevents local and pulmonary albu- 
min leak after lower torso ischemia-reperfusion. Ann.  Surg. 
216:677-683. 
5.  Hill, J., T.F. Lindsay, F.  Ortiz, C.G. Yeh,  H.B.  Hechtman, 
and F.D. Moore, Jr. 1992. Soluble complement receptor type 
1 ameliorates the local and remote organ injury after intestinal 
ischemia-reperfusion in the rat.J. Immunol.  149:1723-1730. 
6.  Pemberton, M., G. Anderson, V. Vetvicka, D.E. Justus, and 
G.D.  Ross.  1993.  Microvascular  effects  of  complement 
blockade with soluble recombinant CR1  on ischemia/reper- 
fusion injury of skeletal muscle.J. Immunol.  150:5104-5113. 
7.  Fearon, D.T., and W.W. Wong.  1983.  Complement ligand- 
receptor interactions that mediate biological responses. Annu. 
Rev. Immunol.  1:243-260. 
8.  Shinkai, Y., G. Rathbun, K.-P. Lain, E.M. Oltz, V. Stewart, 
M. Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, 
and F.W. /kit.  1992.  Rag-2-deficient mice lack mature lym- 
phocytes owing to inability to initiate V(D)J rearrangement. 
Cell. 68:855-867. 
9.  Kobzik,  L.  1993.  Nitric  oxide  synthase  in  human  and  rat 
lung: immunocytochemical and histological localization. Am. 
J. Respir. Cell Mol. Bio. 9:371-377. 
10. Wessels, M.R., P. Butko, M. Ma, H.B. Warren, A. Lage, and 
M.C. Carroll. 1995. Studies of group B steptococcal infection 
in mice deficient in complement C3  or C4 demonstrate an 
essential role  for  complement in  both  innate  and  acquired 
immunity. Pro& Natl. Acad. &i. USA. 92:11490-11494. 
11. Muller-Eberhard,  H.J.  1988.  Molecular  Organization  and 
Function of the  Complement  System. Annu.  Rev.  Biochem. 
57:321-347. 
12. Ross, G.D., and M.E. Medof. 1985.  Membrane complement 
receptors specific for bound fragments of C3. Adv.  Immunol. 
37:217-240. 
13. Holers, V.M., J.L. Cole, D.M. Lublin, T. Seya, and J.P. At- 
kinson.  1985.  Human  C3b  and  C4b  regulatory proteins: a 
new multi-gene family. Immunol.  Today. 6:188-192. 
14. Ravetch, J.V.  1994.  Fc Receptors:  rubor Redux.  Cell. 78: 
553--560. 
15. Ogawa, S., M. Clauss,  K. Kuwabara, R.  Shreeniwas, C. Bu- 
tura, S. Koga, and D. Stem. 1991.  Hypoxia induces endothe- 
lial cell synthesis of membrane associated proteins. Proc. Natl. 
Acad. Sci. USA. 88:9897-9901. 
16. Sanz,  I., P. Casali, J.W. Thomas, A.L. Notkins, andJ.D. Ca- 
pra.  1989.  Nucleotide sequences of eight human natural au- 
toantibody VH regions reveals apparent restricted use of VH 
families.J. Immunol.  142:4054-4061. 
17. Ronda, N., M. Haury, A. Nobrega, S. Kaveri, A. Coutinho, 
and M.D. Kazatchkine. 1994. Analysis of natural and disease- 
associated autoantibody repertoires: anti-endothelial cell IgG 
autoantibody activity in the serum of healthy individuals and 
patients with systemic lupus erythematosus. Int.  Immunol.  6: 
1651-1660. 
18. Leung,  D.Y.M.,  T.  Collins, L.A. Lapierre, and R.S.  Geha. 
1986.  IgM antibodies present in the acute phase of Kawasaki 
syndrome lyse cultured vascular endothelial cells  stimulated 
by gamma interferon.J. Clin.  Invest. 77:1428-35. 
19. Papa, N.D.,  G.  Conforti, D.  Gambini, L. LaRosa, A. Tin- 
cani,  D.  D'Cruz,  M.  Khamashta,  G.R.V.  Hughes,  G.  Bal- 
estrieri, and P.L. Meroni.  1994.  Characterization of the en- 
dothelial  surface  proteins  recognized  by  anti-endothelial 
antibodies in primary and secondary autoimmune vasculitis. 
Clin.  Immunol.  Immunopathol. 70:211-216. 
20. Lorber, M., Z. Kra-oz, B. Guilbrud, and Y. Shoenfeld. 1995. 
Natural  (antiphospholipid-PDH,-DNA) autoantibodies and 
their physiologic serum inhibitors. Isr.  J. Med.  Sci. 31:31-35. 
21. Van  Der  Zee, J.M.,  A.H.M.  Heurkens,  E.A.M.  Van  Der 
Voort, M.R. Daha, and F.C. Breedveld. 1991.  Characteriza- 
tion of anti-endothelial antibodies in patients with rheuma- 
toid arthritis complicated by vasculitis. Clin.  Exp.  Rheum.  9: 
589-594. 
22. Amsterdam, E.A., G.L. Stahl, H.-L. Pan, S.V. Rendig, M.P. 
Fletcher, andJ.C. Longhurst. 1995.  Limitation ofreperfusion 
injury by a monoclonal antibody to C5a during myocardial 
2347  Weiser et al.  Brief  Definitive Report infarction in pigs. Am. J. Physiol.  268:448-457. 
23.  Marks, R.M.,  R.F. Todd, III, and P.A. Ward. 1989.  Rapid 
induction of neutrophil-endothelial adhesion by endothelial 
complement fixation. Nature (Lond.).  339:314-316. 
24. Petrasek, P.F., S. Liauw, A.D. Romaschin, and P.M. Walker. 
1994.  Salvage of postischemic skeletal muscle by monoclonal 
antibody blockade of neutrophil adhesion molecule CD 18. J. 
Surg.  Res. 56:5-12. 
25. Ma,  X.L.,  P.S.  Tsao,  and  A.M.  Lefer.  1991.  Antibody to 
CD 18 exerts endothelial and cardiac protective effects in my- 
ocardial ischemia and reperfusion./. Ctin.  Invest. 88:1237-1243. 
26. Vedder, N.B., R.K. Winn, C.L. Rice, E.Y. Chi, K.E. Arfors, 
and J.M. Harlan. 1990.  Inhibition of leukocyte adherence by 
anti-CD18  monoclonal antibody attenuates  reperfusion in- 
jury in the rabbit ear. Proc. Natl.  Acad.  Sci.  USA.  87:2643- 
2646. 
27.  Seekamp,  A.,  G.  Till,  M.S.  Mulligan, J.C.  Paulson,  D.C. 
Anderson, M.  Miyasaka, and P.A. Ward.  1994.  Role of se- 
lectins in local and remote tissue  injury following ischemia 
and reperfusion. Am. J. Pathol.  144:592-598. 
2348  Reperfusion Injury Is Mediated by Natural Antibody and Complement 